The Royal Marsden The delayed effects of disease and treatment interventions on individuals who have had Head and Neck Cancer Welcome to the National Study Day 2013 The Royal Marsden This Head and Neck Cancer Study Day Aims – To provide time to reflect on practice – New information on old issues – Provide updates on areas which will impact on our patient population – Question current ways of working – Network with others in the field – Inspire and motivate Enjoy your day The Royal Marsden “I felt as if my illness were a blanket the world had thrown over me; all that could be seen from the outside was an indistinguishable lump” (Lucy Grealy 1994) The Royal Marsden Managing the complexity of ‘Oral Mucositis’ and potential Oral Complications for individuals who have treatment for a head and neck cancer Sonja Hoy Clinical Nurse Specialist Head, Neck Thyroid and Radiation Protection The Royal Marsden A Neglected Task Despite its acknowledged importance, oral care is one of the first things to be set aside when workloads are excessive (McGuire 2003) The mouth is an important aspect of cancer care, all too often this aspect of care may be overlooked until problems arise. This leads to needless distress and discomfort and in some cases serious clinical consequences. (European Journal of Cancer Care 2009) The Royal Marsden A study in 2002 by Rose-Ped and colleagues conducted 33 interviews of patients who had completed radiotherapy for Head and Neck cancer reporting Oropharyngeal Mucositis as the most debilitating side effect. (Cancer Nursing 2002) The Royal Marsden Aim of the session – A greater understanding of Oral Mucositis and its aetiology – Understanding the morbidity for the individual experiencing Oral Mucositis – Recognition the acute and delayed effects of treatment on the oral mucosa – Strategies that may influence care and follow-up after treatment The Royal Marsden How we can define Oral Mucositis As an inflammation of the mucosal membrane, characterised by ulceration resulting in severe discomfort and pain, dysphagia, impairs the individual’s ability to talk, eat and swallow. Mucosal injury provides an opportunity for infective agents to flourish placing the individual at risk of bacteraemia and sepsis ( Rubenstein, Peterson, Schubert, Keefe, McGuire, Epstein, et al, 2004). The Royal Marsden What are the statistics? • Incidence of OM in head and neck cancer patients quotes mean incidence of 80% (Trotti 2003, Worthington et al 2006) • Remains under reported • It is under appreciated by some health care professionals (Moutesim & Tappuni 2008) • The effect of Oral Mucositis on the individual is profound, debilitating and can lead to treatment interruptions and hospitalisation The Royal Marsden What are the main chemotherapy agents that alter the mucosal tissue? – 5FU bolus causing more mucotoxic damage than infusion regimes – Docetaxel – Doxorubicin – Cyclophosphamide – Methotrexate (folinic acid rescue) – Melphalan – Begins around 4 to 5 days post chemotherapy lasting for about 5 days (Sonis 2007), Sonis et al 2004) The Royal Marsden Radiotherapy impact on mucosal tissue – Changes to the oral mucosa are seen after only an accumulated dose of 10Gy – In most cases ulceration is seen at 30Gy the end of only the 3rd week or middle of treatment for Head and Neck Cancers – Continues for up to 6 weeks post completion of the 6 weeks of treatment – Tonsil and base of Tongue tumour sites have a large area of the mucosal tube irradiated – Those receiving chemotherapy and radiotherapy are at significant risk of developing OM (Sonis et al 2004, Sonis 2007) The Royal Marsden Pathobiology of Mucositis The Royal Marsden Normal Mucosal Epithelium The Royal Marsden Historic Pathobiologic view of Oral Mucositis – Based on the views that cytotoxic treatments kill rapidly dividing cells; like those in the renewing epithelium – Thus leading to an imbalance in the equilibrium of epithelial loss and replenishment (Keefe et al 2007) – Once enough damage to the epithelium occurred to thin it to breaking point ulceration occurred – Bacterial colonization, secondary infection was thought to contribute to ulceration and its continued development, duration impacting on healing – Approaches were then developed on the view that Oral Mucositis had an infectious aetiology The Royal Marsden What is the new evidence? – Early tissue damage using morphological evidence from histology and electron microscopes identified that early damage was seen in the sub-mucosa before any clinical signs – This corresponds with patient reported symptoms without any visible signs clinically – So what was happening in the sub-epithelial tissue was apoptosis of fibroblasts and micro-vasular endothelial cells not dying epithelium – Therefore microscopic damage is occurring much earlier than clinically detectable damage to the epithelium – Signalling from the damaged sub-mucosa cells to the epithelium mediates (communicates) epithelial damage/injury – The endothelium or sub-mucosa acts as a foundation both physically and bio-chemically to the epithelium. When the foundation is lost then the epithelium collapses The Royal Marsden Oral Mucositis A final common pathway... Normal epithelium Phase 1 Initiation 0-2 Days Sonis S et al. Cancer 2004;100:(9 Suppl):1995–2025 Phase 2/3 Messaging, signaling, amplification Phase 4 Ulceration (mucositis) Phase 5 Healing 2-10 Days 10-15 Days 14-21 Days The Royal Marsden Cytokines in the development of Oral Mucositis – Increases in pro-inflammatory cytokines are associated with the development of Oral Mucositis – They play important roles in mediating injury and in signalling pathways – Pro-inflammatory cytokine levels such as tumour necrosis factor (TNF), interleukin 6 (IL-6) and interleukin-1beta (IL-1B) increase before tissue damage is apparent – Much of the tissue damage seen is due to the consequence of apoptosis The Royal Marsden Apoptosis (cell death) – Apoptosis is seen as a result of chemotherapy and radiotherapy induced damage within the sub-mucosa – Enhanced apoptosis exacerbates the risk of Oral Mucositis – The data seems to suggest the idea that apoptosis and its regulation are critical factors in the development of Oral Mucositis (Paris et al 2001) The Royal Marsden Patho-physiology – Initiation of tissue damage (Chemotherapy and or Radiotherapy treatment) – Upregulation of inflammation (Apoptosis) – Signalling and amplification (Cytokine activity) – Ulceration and infection (damage to the submucosa and collapse of the epithelium) – Healing (Sonis 2007) The Royal Marsden Mucosal Damage: a Complex Biological Process Adapted from Sonis ST. Cancer. 2004;100(suppl 10):1995-2025. The Royal Marsden Initiation – Occurs immediately after the administration of radiation or chemotherapy. Therefore in radiation treatment initiations events are chronological – Direct damage to DNA can cause immediate cell death in the basal epithelia and sub-mucosal cells – The chemotherapeutics and ionising radiation generate reactive oxygen species (ROS) that damage connective tissue, DNA, and cell membranes; stimulate macrophages and a cascade of critical biologic mechanisms, molecules and pathways. (Sonis 2007) The Royal Marsden Primary Damage Response – Activation of a number of signalling pathways from chemotherapy and radiation, damage cells – These damaged cells with their damaged DNA indirectly precipitate the beginning of the biologic process that results in mucosal injury (Sonis 2007) The Royal Marsden The Royal Marsden Signal Amplification – Multiple sources of damage leads to message generation activating normal damage response pathways – Many of the proteins produced during this primary damage response stimulate additional injury through positive feedback loops. TNF activates NF-xB, NF-xB initiates nitrogen-activated protein kinase (MAPK) – Feedback loops magnify the response and prolong damage by continuing to provide signals for days after primary injury The Royal Marsden The Royal Marsden Ulceration – At this stage we clinically see the significant damage/ injury – The ulcerations are deep, broad and painful – Visuably they are covered with a pseudo membrane made up of dead cells and fibrin – This is then a very desirable environment for secondary infections commonly gram +ve and gram –ve organisms – They can then invade the submucosa and cause bacteremias – In patients with altered WBC then there is significate risk of sepsis – This process also initiates macrophage pro-inflammatory cytokine production (amplifying the situation) The Royal Marsden Oral mucosal damage and infection – The mouth’s mucosa is a rich environment of bacteria, fungi and viruses – A portal of entry into the body – Awareness that specific oncology patients are at risk the elderly and children along with those which have an altered neutropenic status (Sonis et al 2007, Keefe et al 2007) The Royal Marsden The Royal Marsden Healing – This is the least understood phase – Starts to resolve spontaneously about 2-3 weeks after treatment – Cyclooxygenase (COX-2) expressed by the fibroblasts and vascular epithelium may play a role in rebuilding the submucosa as it potentates angiogenesis – This signals and end of the ulcerative stage – After repair it is interesting that the epithelium or the structure of the sub-mucosa is not the same state pre mucotoxic damage The Royal Marsden What are the potential opportunities for understanding the pathobiology of mucositis? – With increased understanding of the signalling pathways involved in the development of Mucositis it is allowing us to identify potential therapeutic targets – We must ensure that any interventions protect ‘normal tissues’ whilst avoiding the protection of cancer cells – Greater understanding of the patho-biology of Mucositis will improve the effective use of targeted treatments by understanding what the cellular interactions are – In time we maybe able to tailor treatments regimes with effective prophylaxis and interventions to treat OM The Royal Marsden The Physical impact of Oral Mucositis • Experiencing mild discomfort to fluid and foods to actual trauma and pain • The domino effect of oral pain leads to poor oral care, alteration to communication, poor hydration and nutrition • Open ulcerated areas, tenacious mucus and alteration to salivary function increases risk of nausea and vomiting, local and systemic infection • Increases in anxiety and fatigue • Further damage and pain if N&V is not controlled • Altered biochemistry can be compounded by Cisplatin The Royal Marsden The Psycho-social impact of Oral Mucositis • Impact on individual enjoy-ability and QOL associated with food • Sharing a meal or drink are an integral part of socialising experiencing loss, anger… • Disengagement in what is seen as everyday activities of living, increasing social isolation (Rubenstein et al 2004) • Fear around individual appearance a visual disclosure of disease • Impact on verbal communication • Frustration, anxiety and depression (Wong et al 2006) • Financial and economic burden of treatment and recovery (Lalla et al 2006) The Royal Marsden What are the key interventions ? – Basic oral hygiene assessment and care planning (Keefe et al 2007) – Nurses leading oral care, oral assessment and education – Initial dental assessment, extractions with an established hygiene protocol, with a hygienist throughout and post treatment – Smoking cessation planning involvement of community teams (DOH, WHO and improving clinical outcomes data) – Alcohol detoxification prior to commencement of determined modalities – Tailored educational interventions (Armstrong & McCafferty 2006) The Royal Marsden Assessment The Royal Marsden Pre-treatment morbidity factors • • • • • • • • • Poor oral hygiene and poor nutrition Smoking and/or Alcohol intake Age Planned treatment pathway Other medications Oxygen therapy Co-morbidities Educational status HPV status These may impact on severity and length of Oral Mucositis The Royal Marsden Recommendations- Smoking – Increased risk of progression/recurrence if continue smoking after treatment – Poorer outcomes in survival in those that smoke prior to diagnosis – HNCa patients that carry on smoking during Radiotherapy found to suffer from mucositis for average of 23.4 weeks in comparison with 13.6 weeks in the non-smokers, (Webb, 2008) The Royal Marsden Dentate Patients – Pre treatment dental assessment – Encourage regular dental check ups – Antibiotic cover required for extraction if within XRT field – Fluoride crucial for dentate patients – Brush with pea sized amount of fluoride toothpaste – Saline or salt water rinses The Royal Marsden Edentulous Patients – – – – – – Examine oral cavity with dentures removed Inspect dentures over a sink of water Scrub with nail/toothbrush & soap daily Remove dentures & rinse with water after meals Soak dentures overnight in water If oral infection present, soak dentures overnight to disinfect The Royal Marsden World Health Organisation (WHO) – Most widely used instrument – Addresses all 3 components of OM – Objective signs (ulceration) – Subjective symptoms (pain) – Functional disturbances (inability to eat) – Widely regarded as the gold standard – Never been tested for reliability – The tool we use in daily practice at Christie The Royal Marsden Assessment of Oral Mucositis Mucositis Grade Scale 0 1 WHO Oral Toxicity 1 Scale None Soreness and erythema 2 Erythema, ulcers, patient can swallow solid diet 3 4 Ulcers, extensive erythema, patient cannot swallow solid diet Mucositis to extent that alimentation not possible WHO = World Health Organization World Health Organization. Handbook for reporting results of cancer treatment. 1979;pp. 15-22. 1 The Royal Marsden Oral Assessment The Royal Marsden Erythema – No Pain – Yes Diet - Solids The Royal Marsden Erythema – Yes Pain – Yes Diet - Solids The Royal Marsden Erythema – Yes Pain – Yes Diet - NPO The Royal Marsden Erythema – Yes Pain – No Diet - Solids The Royal Marsden Erythema – Yes Pain – Yes Diet -NPO The Royal Marsden Erythema – Yes Pain – Yes Diet - NPO The Royal Marsden Erythema – No Pain – No Diet - Solids The Royal Marsden Erythema – No Pain – Yes Diet - Solids The Royal Marsden Erythema – Yes Pain – Yes Diet - Liquids The Royal Marsden Erythema – Yes Pain – Yes Diet - Liquids The Royal Marsden So what are the products out there in the literature? – – – – Allopurinol mouth washes Immunoglobulin’s Human placental extract Bendzydamine HCL (Cheng et al 2006). Kazemian et al 2009 study reduced grade 3 mucositis from 78.6% in placebo group to 43.6 % in the Bendzydamine arm (Diffllam oral rince). Is a NSAID and stops the release of prostaglandins after tissue injury – Sucralfate contra-indicated in Head and neck setting – Chlorhexidine and Tetrachlorhexidine for dental health not Oral Mucositis – Magic mouth wash (lidocaine solution, dipenhydramine hydrochloride, aluminium hydroxide suspension) – Saline The Cochrane review concluded that RCT multi-centre studies were needed to determine efficacy and best practice The Royal Marsden The old and the new products – Caphosol: prevention and treatment, rich in both calcium and phosphate ions. It works by lubricating the mouth - keeping it clean and moist - and making food easier to swallow (Miyamoto et al 2009, Haas et al 2008) – Mugard: prevention and treatment is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa – Oralbase – Amifostine: issues around its radio-protection activity and protection of tumour cells (Grau et al 2004) – Pilocarpine used for late effect xerostomia (Grau et al 2004) – Biotene products – Artifical saliva: AS Saliva Orthana, Biotene oral balance, Bioxtra, Glandosane, Luborant. Newer products are Zerotin and Aquaoral The Royal Marsden Treatment of Therapy-Induced Mucositis from the UKOMIC group Grade 1 or 2 Mucositis – – – – – – – Ensure oral hygiene is adequate. Consider increasing the frequency of saline rinses. Consider the need to remove dentures if they are irritating. Closely monitor nutritional status and refer to dietician if eating and drinking are affected. Provide simple analgesia, which may include soluble paracetamol 1 g four times daily (two tablets should be dissolved in water and used as a mouthwash). It should be remembered that paracetamol may mask fever. Escalate to soluble co-codamol 30/500 if required. The use of NSAIDs is contraindicated due to the risk of bleeding and renal impairment (Keefe et al., 2007). Consider benzydamine 0.15% oral solution (Difflam®), 10 ml rinsed around the mouth and spat out. Repeat between every 1.5 to 3 hours, as required. If the patient complains of stinging, dilute 10 ml of Difflam® with 10 ml of water prior to administration and use 10 ml. However, this may be poorly tolerated in patients receiving head and neck radiotherapy and in any patient with severe mucositis. Check to see if the patient has evidence of oral infection and if so ensure an antiinfective agent is prescribed Consider Caphosol® (4–10 times a day) to prevent grade 1 and 2 OM becoming more severe. The Royal Marsden Treatment of Therapy-Induced Mucositis from the UKOMIC group 2012 Grade 3 or 4 Mucositis In addition to the recommendations for grade 1 and 2 OM, the following should be considered: – Use of stronger analgesia, including Oxynorm®, Sevredol® and Oramorph® to alleviate pain (Oramorph® may sting mucosa due to its alcohol base). If patients continue to suffer from pain from mucositis, consider using further opioid analgesia, such as fentanyl patches, patient-controlled analgesia or a syringe driver (seek advice from the acute pain team or the palliative care service). Laxative medications should be prescribed to prevent constipation and associated nausea. – Ensure intravenous and/or enteral hydration and feeding is prescribed, as oral intake may be reduced (following consultation with the dietician). – Consider Caphosol® (4–10 times a day). – Consider applying a coating protectant, e.g. Gelclair®, MuGard®, Episil®. The product should be rinsed around the mouth to form a protective layer over the sore areas, and generally applied 1 hour before eating. The Royal Marsden The potential oral complications after treatment The Royal Marsden Physical issues post radiation therapy – – – – – – – Xerostomia and Hyposalivation (Haas & McBride2011) Dental Caries Peridonal disease Dygeusia: Taste changes (Consider Zinc therapy) Persistant dysphagia (refer to SALT) Dysphonia Trismus can range from 10-40% of patients and increases the risk of aspiration due to the restriction of the muscles used to breakdown food (Carper 2007) – Fungal Infections – Osteoradionecrosis Epstein et al 2001 reported a dry mouth moderate to severe in 70 % of patients post treatment The Royal Marsden Xerostomia “The challenge is for practitioners to revise the mundane through reflection and to review it as the sacred” (Freshwater 1998) The Royal Marsden The salivary glands – In addition to small salivary glands, there are three large salivary glands, including the parotid glands, submandibular glands, and sublingual glands on each side of the mouth – Saliva serves to maintain oral moisture, to reduce tooth decay, and to assist in digestion – Besides, saliva acts as a natural neutralizer of stomach acid when it refluxes into the oesophagus – Main salivary glands Parotid, sub-mandibular and sub-lingual produce approximately 80% of saliva and this is produced within seconds from a stimuli; smell, taste and sight – Parotids produce the serous component while the other minor glands produce the mucus – We normally produce 1-1.5 litres of saliva per daily (Cheng et al 2004) The Royal Marsden Xerostomia – Defined as dry mouth resulting from reduced or absent saliva flow – A well know side effect of radiation to the head and neck (Haas & McBride 2011) – A possible side effect of a wide variety of medications and may or may not be associated with decreased salivary gland function – What is interesting is Xerostomia is a common complaint affecting approximately 20 percent of the older adult population, however it maybe older adults often have a variety of medications and the side effect of these may be Xerostomia – (Cathy L. Bartels 2000-2013 OCF Montana) The Royal Marsden Saliva substitutes do not stimulate saliva • Glandosane® (Kenwood/Bradley) spray • Xerotin ® spray (SpePharma) • Saliva Substitute® (Roxane Labs) liquid • Salivart® (Gebauer) preservative-free aerosol • Salix® (Scandinavian Natural Health & Beauty) tablets • V. A. Oralube® (Oral Dis. Res. Lab) sodium-free; liquid • Xero-Lube® Artificial Saliva (Scherer) sodium-free; spray • Biotene® Gentle Mouthwash • Biotene® Dry Mouth Gum • Oralbalance® Long-lasting Moisturizing Gel • Biotene® Dry Mouth Kit • Biotene® Dry Mouth Toothpaste The Royal Marsden The Psycho-social impact of Oral Mucositis • • • • • • Independence vs dependence On going side effects remind patient of their disease Social isolation versus socialisation Impact on intimacy, sexuality and relationship changes Treatment many weeks; recovery is many months to years Cyclical anticipation issues due to the expected mucositis and or expected and experienced pain (Haas & McBride 2011) The Royal Marsden What is the way forward? The Royal Marsden Continue with the interventions we have available today – Imaging prior to commencing treatment – IMRT – Removal of any teeth that may show signs of peridontal disease prior to EBRT; at least 14 days between extractions and starting treatment – Life long use of fluoride (trays or high fluoride tooth paste) – Life long commitment to strict oral hygiene – Oral hydration – Pharmacology products for xerostomia – Acupuncture – Therabite jaw rehabilitation (Haas and McBride 2011) – Anti-fungal therapy – Education and empowering the patients – Community facilities for Nurses, Dieticians and SALT The Royal Marsden Thinking beyond 2013…. The wider context: – – – – – – – Collaboration of interventions and supportive care (de Castro & Guindalini 2010) National Guidance and standardisation for OM (see EONS 2011, UKOMIC 2012) Audit and research (Worthington et al 2006, Harris et al 2008) Randomised controlled multi centre studies Honesty about the limitations of managing OM Adequate pain relief during treatment and recovery Utilising other methods to identify at risk patients who may require early and prolonged interventions e.g. HAD scale, FACIT assessment tool, distress thermometer, oral assessment tools and protocols (Harris et al 2008, Hogan 2009, Hass & McBride 2011) The Royal Marsden ... how? – Collaboration with HCP and challenging the boundaries of care – Rationalisation of resources: establishing what resources we have and how best they can be utilised (Wells et al 2007) – A greater political voice about oral care and cancer care (political targets verses the individual assessed need) – Health promotion model which is aimed at prevention rather than cure – Voice of the users: Support groups for those living with cancer – Further clinical trials and assessment of products The Royal Marsden Conclusion Oral Mucositis is expected in 98% of our patient population, and remains a very serious complication in head and neck cancer treatment. Oral Mucositis has a profound effect on morbidity, compliance and treatment outcomes. It can significantly lead to post treatment oral complications that are potentially life long (Haas and McBride 2011) Health Care Professionals can make significant contributions to the management of Oral Mucositis and Oral Complications by challenging boundaries and care delivery. With limitations comes creativity! The Royal Marsden
© Copyright 2024